Navigation Links
AndroScience Corporation Announces Phase 2a Study Results on ASC-J9(TM) for the Treatment of Acne
Date:3/6/2009

SAN DIEGO, March 6 /PRNewswire/ -- AndroScience Corporation (ASC(TM)), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9(TM) cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.

ASC-J9(TM) demonstrated a clinical benefit in reducing inflammatory lesions compared to placebo at certain dosages and at multiple time points during the study, though the study was not powered for statistical significance. ASC will now focus on bolstering efficacy through a new formulation and intends on forming a co-development or licensing partnership for future clinical development and commercialization. Through enhancing androgen receptor protein degradation, ASC-J9(TM) represents the first topical agent directed at modulating the effect of androgens (male hormones), through the androgen receptor, a key causative factor in the pathogenesis of acne.

Charles Shih, Ph.D., Chief Executive Officer of AndroScience Corporation, said, "We are extremely enthusiastic about the therapeutic potential of ASC-J9(TM) and the remarkable safety profile exhibited by the drug. The 0.025% cream formulation dose of ASC-J9(TM) delivered a therapeutic benefit comparable to levels seen with marketed acne drugs on inflammatory lesions, with no side effects, and we believe a higher dosage or improved formulation will translate to even greater efficacy in the treatment of acne."

ASC-J9(TM) is a small molecule with a novel mechanism of action, which selectively enhances androgen receptor degradation (ARD) to reduce androgen activity. ARD enhancers act on a key cause of acne, the androgen activation system, through reducing high levels of androgen receptor present in the sebaceous gland to lower sebum secretion, a fundamentally different approach from all other current acne treatments. ASC-J9(TM) cream is topically administered and exhibits low systemic absorption, limiting systemic side effect risks and allowing for the treatment of both males and females.

In addition to acne indication, AndroScience is currently pursuing androgenetic alopecia (male pattern baldness), and wound healing using topical based formulations; and prostate cancer, benign prostatic hyperplasia, and spinal bulbar muscular atrophy (Kennedy's Disease - a neuron motor disease caused by AR mutation) utilizing systemic based approaches.

AndroScience Corporation

www.androscience.com


'/>"/>
SOURCE AndroScience Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Licenses Naturally Derived Compound For Scar Improvement; License Requires Payments Totaling $1.1 Million To The Quigley Corporation Over A Five Year Period For Exclusive Ownership
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Chemstar Corporation Offers Comprehensive Deep Cleaning Programs to Combat Salmonella, Listeria, and E. coli in Retail Supermarkets
4. Christie Cookie Recalls Certain Lots of Peanut Butter Cookie Dough Due to Expanded Recall by Peanut Corporation of America
5. AGA Medical Corporation Launches Web-Based Stroke Education and Awareness Program Featuring Professional Football Player Tedy Bruschi
6. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
7. PDS Biotechnology Corporation Progresses Development of Nanotechnology Cancer Therapies
8. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
9. Chemstar Corporation Announces a New Powerful, One-Step Product That Effectively Controls Listeria, Salmonella, E. coli and Fly Larvae in Floor Drains
10. Successful Results for Mymetics Corporations Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceeds Expectations
11. National Jewish Health and Roche Diagnostics Corporation Reach Agreement to Pursue Environmental Molecular Diagnostics Opportunities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/25/2016)... Austin, TX (PRWEB) , ... June 25, 2016 , ... ... Fellow of the American College of Mohs Surgery and to Dr. Russell Peckham for ... popular and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... ... the United States, named Dr. Sesan Ogunleye, as the Medical Director of its new ... the facility Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary ... Work award to iHire in recognition of their exemplary accomplishments in worksite health promotion. ... Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
Breaking Medicine News(10 mins):